{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:29:08Z","timestamp":1769171348121,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1016\/s0969-8051(01)00290-6","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T09:03:24Z","timestamp":1027587804000},"page":"147-157","source":"Crossref","is-referenced-by-count":80,"title":["Ga-66 labeled somatostatin analogue DOTA-DPhe 1 -Tyr 3 -octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors"],"prefix":"10.1016","volume":"29","author":[{"given":"\u00d6mer","family":"Ugur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paresh J","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald D","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pat","family":"Zanzonico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shutian","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilonka","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut R","family":"Maecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0969-8051(01)00290-6_BIB1","first-page":"1929","article-title":"D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake","volume":"38","author":"Bernard","year":"1997","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s002590050488","article-title":"Peptide radiopharmaceuticals in nuclear medicine","volume":"26","author":"Blok","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0020-708X(71)90082-2","article-title":"Chemical Processing of Cyclotron-Produced 67Ga","volume":"22","author":"Brown","year":"1971","journal-title":"Int. J. Appl. Radiat. Isot."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0026-0495(96)90072-4","article-title":"Binding properties of somatostatin receptor subtypes","volume":"45","author":"Bruns","year":"1996","journal-title":"Metabolism."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/77.3.739","article-title":"Complete tumor ablation with iodine-131 radiolabeled disialoganglioside GD2 specific monoclonal antibody against neuroblastoma xenografted in nude mice","volume":"77","author":"Cheung","year":"1986","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB6","first-page":"1837","article-title":"Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas","volume":"80","author":"Epelbaum","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB7","first-page":"429","article-title":"The use of radionuclides for tumor therapy","volume":"13","author":"Fawwaz","year":"1986","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0928-4257(00)00208-4","article-title":"Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery","volume":"94","author":"Fehlmann","year":"2000","journal-title":"J. Physiol. Paris."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB9","first-page":"3652","article-title":"Differential regulation of somatostatin type 2 receptor (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide therapy","volume":"59","author":"Froidevaux","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10799899909036643","article-title":"A microplate binding assay for the somatostatin type-2 receptor (SSTR2)","volume":"19","author":"Froidevaux","year":"1999","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB11","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1210\/endo.141.9.7683","article-title":"Preclinical comparison in AR4-2J tumor bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid somatostatin analogs for tumor diagnosis and internal radiotherapy","volume":"141","author":"Froidevaux","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/S0969-8051(01)00290-6_BIB12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1118\/1.597924","article-title":"An investigation of the physical characteristics of 66Ga as an isotope for PET imaging and quantification","volume":"24","author":"Graham","year":"1997","journal-title":"Med. Phys."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bjc.1993.266","article-title":"Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue","volume":"67","author":"Hammond","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0969-8051(01)00290-6_BIB14","first-page":"1053","article-title":"PET imaging of somatostatin receptors using 68Ga-DOTA0-D Phe1-Tyr3-Octreotide (DOTATOC)","volume":"42","author":"Henze","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB15","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0.CO;2-X","article-title":"Radiometal-labelled macrocyclic chelator derivatised somatostatin analogue with superb tumor targeting properties and potential for receptor mediated internal radiotherapy","volume":"5","author":"Heppeler","year":"1999","journal-title":"Chem. Eur. J."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/0929867003374516","article-title":"Receptor targeting for tumor localization and therapy with radiopeptides","volume":"7","author":"Heppeler","year":"2000","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB17","first-page":"312P","article-title":"Quantitative [Ga-68]-DOTATOC SMS receptor PET and planar [Ga-67]-DOTATOC SMS receptor scintigraphy in the pre-therapeutical dosimetry of neuroendocrine tumors","volume":"42","author":"Hofmann","year":"2001","journal-title":"J. Nucl. Med."},{"issue":"suppl 2","key":"10.1016\/S0969-8051(01)00290-6_BIB18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabeled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB19","first-page":"1704","article-title":"Peptide receptor imaging and therapy","volume":"41","author":"Kwekkeboom","year":"2000","journal-title":"J. Nucl. Med."},{"issue":"Suppl.","key":"10.1016\/S0969-8051(01)00290-6_BIB20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/1097-0142(19910215)67:4+<1253::AID-CNCR2820671523>3.0.CO;2-J","article-title":"Radioimmunology","volume":"67","author":"Larson","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/S0969-8051(01)00290-6_BIB21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/abio.1996.0176","article-title":"Measurement of p-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay","volume":"236","author":"Levchenko","year":"1996","journal-title":"Anal. Biochem."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cbr.2000.15.593","article-title":"Comparative dosimetry of copper-64 and yttrium-90 labeled somatostatin analogs in a tumor-bearing rat model","volume":"15","author":"Lewis","year":"2000","journal-title":"Cancer Biotherapy Radiopharm."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB23","first-page":"171","article-title":"A new generator for ionic gallium-68","volume":"21","author":"Loc\u2019h","year":"1980","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin-analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0969-8051(01)00290-6_BIB25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC","volume":"26","author":"Otte","year":"1999","journal-title":"Eur. J Nucl. Med."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Recepetor mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1095-0397(00)00046-7","article-title":"Quantitative imaging of yttrium-86 with PET","volume":"3","author":"Pentlow","year":"2000","journal-title":"Clin. Positron Imaging"},{"key":"10.1016\/S0969-8051(01)00290-6_BIB28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB29","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/0024-3205(81)90628-7","article-title":"High affinity binding sites for a somatostatin-28 analog in rat brain","volume":"28","author":"Reubi","year":"1981","journal-title":"Life Sci."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s002590050398","article-title":"Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue","volume":"26","author":"Rosch","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"issue":"Suppl 1","key":"10.1016\/S0969-8051(01)00290-6_BIB31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000051858","article-title":"OctreoTher","volume":"62","author":"Smith","year":"2000","journal-title":"Digestion"},{"key":"10.1016\/S0969-8051(01)00290-6_BIB32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s002590050268","article-title":"The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumors","volume":"25","author":"Stolz","year":"1998","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0969-8051(95)02001-2","article-title":"Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma","volume":"23","author":"Ugur","year":"1996","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/S0969-8051(01)00290-6_BIB34","first-page":"82","article-title":"MIRD","author":"Weber","year":"1989"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805101002906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805101002906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,4]],"date-time":"2019-05-04T15:26:16Z","timestamp":1556983576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805101002906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0969805101002906"],"URL":"https:\/\/doi.org\/10.1016\/s0969-8051(01)00290-6","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}